Alcon

Clareon® PanOptix®
Trifocal IOL &
Toric Trifocal IOL

NO ONE DREAMS OF SILVER

START ›

The Clareon® PanOptix® Sales Aid (for PanOptix® users)

*Based on global Clareon® PanOptix® and AcrySof® PanOptix® unit sales

Alcon

Clareon® PanOptix®
Trifocal IOL &
Toric Trifocal IOL

What would it mean to you to have a PanOptix® IOL with unsurpassed clarity characteristics?

Clarity of an IOL help reduce the Post-op Evidence of Glistenings

Clarity is more than just glistenings

What defines a Pristine IOL?

Alcon

Clareon® PanOptix®
Trifocal IOL &
Toric Trifocal IOL

Clareon® PanOptix® IOL:
An exceptional visual experience on Alcon's most advanced lens platform[2,3]

20/20 vision at far, intermediate and near[3^]

A more natural intermediate focal point at 60 cm vs 80 cm[4^]

99% patient satisfaction[3^]

Unsurpassed clarity & stability[5-12]

PanOptix® awarded “Best Medical Technology”

Prix Galien is an international award recognizing innovating therapies. Largely considered the Nobel Prize of the biopharmaceutical and **medical technology** industries, Prix Galien honors innovations rigorously selected as **life-changing** therapeutics each year.[13]

2020 Winner

Entresto
Heart failure treatment
Novartis

2021 Winner

AcrySof® IQ PanOptix®
Trifocal Intraocular Lens
Alcon

2022 Winner

Comirnaty
COVID-19 vaccine
Biontech & Pfizer

Clareon® PanOptix® delivers 20/20 vision at near, intermediate and far[3^]

Vision Simulation: Daytime Activity

A Pooled Analysis of Multiple Studies Demonstrated That PanOptix® Provides a Continuous Range of Vision from Distance to Near[14^]

Mean binocular clinical defocus curve at 3–6 months* (n=542)



20/20 visual acuity is now possible at distance, intermediate (66cm), and near (40cm), as well as 20/25 or better at the very near (33cm)

^Based on AcrySof® IQ PanOptix® data Clareon® IOLs are optically equivalent to AcrySof® IQ IOLs
*Pooled analysis data is from six individual studies. †Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means ≥3 of the 5 ETDRS chart letters in the line were identified correctly. logMAR, logarithm of the minimum angle of resolution; VA, visual acuity. Alcon Research LLC. 2021. AcrySof® PanOptix® Pooled Defocus Curve.

Clincal outcomes of AcrySof® IQ PanOptix® vs Clareon® PanOptix®[15]

Lee et al. BMC Ophthalmology (2022) 22:379
https://doi.org/10.1186/s12886-022-02600-x

BMC Ophthalmology

RESEARCH Open Access

Clinical outcomes of new multifocal intraocular lenses with hydroxyethyl methacrylate and comparative results of contrast sensitivity, objective scatter, and subjective photic phenomena

Yong Woo Lee[1,2,3], Chul Young Choi[4], Kun Moon[3], Yong Jin Jeong[3], Sang Il An[3], Je Myung Lee[3], Jong Ho Lee[3] and Min Cheol Seong[2,5*]

Abstract

Background: We investigate the performance of new hydrophobic diffractive multifocal intraocular lenses (IOL) with hydroxyethyl methacrylate (HEMA) and compare their optical quality, contrast sensitivity, and subjective photic phenomena.

Methods: Medical records of patients who underwent routine simple cataract surgery and insertion of an existing multifocal IOL (TFNT, TF group) or a new multifocal IOL (CNWT, CN group) were retrospectively reviewed. Clinical data was collected 2 months postoperatively and included optical quality analysis system (OQAS) indices, contrast sensitivity, and subjective degrees of photic phenomena.

Results: One hundred thirty-five eyes of 135 patients were included (CN group, 71; TF group, 64). There was no significant difference between the two groups in the visual acuity and defocus curve. The indices of OQAS did not show a significant difference between groups. Contrast sensitivity was significantly better in the CN group at all degrees, including the area under the log contrast sensitivity function ($p = 0.01$). The subjective photic phenomena survey showed better results for the CN group, with the proportion of patients reporting no photic phenomena as 9.9% and 3.1% in the CN and TF groups, respectively. The proportion of patients who reported severe photic phenomena was 11.3% in the CN group and 25.0% in the TF group. Although the follow-up period was only 2 months, glistening, surface scattering, and posterior capsule opacity were not observed in any patient.

Conclusions: The new multifocal IOL with HEMA is safe, and provides stable visual acuity as well as superior contrast sensitivity and lower subjective photic phenomena, over the prior IOL.

Keywords: Hydroxyethyl methacrylate, Multifocal intraocular lens, Contrast sensitivity

In a retrospective study with 135 patients, Clareon® PanOptix® demonstrated:

Significantly better contrast sensitivity vs AcrySof® IQ PanOptix®° ✓

Significantly less visual disturbances vs AcrySof® IQ PanOptix®° ✓

°Contrast sensitivity was significantly better in the Clareon PanOptix group at all degrees, including the area under the log contrast sensitivity function (p = 0.01); 6.3° = 0.019 vs 0.026; 4.0° = 0.02 vs 0.03; 2.5° = 0.026 vs 0.037; 1,6° = 0.045 vs 0.059; 1.0° 0.078 vs 0.105; 0.64° = 0.156 vs 0.201

Clincal outcomes of AcrySof® IQ PanOptix® vs Clareon® PanOptix®[15]

Subjective photic phenomena survey of Clareon® PanOptix® and AcrySof IQ Panoptix®*[15]



Comparison of contrast sensitivity (AULCSF)[15]



*Subjective photic phenomena survey from the Clareon® Panoptix® and Acrysof® Panoptix® groups
AULCSF area under the log contrast sensitivity function.

Natural intermediate focal point is at arm's length[16-19^]





Why 60 cm vs. 80 cm Matters to Patients

A person would need to be about 205 cm tall for 80 cm to be considered a comfortable arm's length[16-19]

- Intermediate tasks are often done at arm's length
- Human factor surveys and the Occupational Safety and Health Administration (OSHA) recommend 60 cm for comfortable computer work[16-17]
- **80 cm = arm's length of a person ~205 cm tall[18-19]**



RESULTS

Significantly higher patient satisfaction with better UIVA at 60 cm vs 80 cm[16]

PanOptix® delivers proven patient satisfaction[2,3^]

Based on data collected
6 months post-op,

of patients would have **the same lens implanted again.**

Learn more about validated patient visual quality +

^Based on AcrySof® IQ PanOptix® data Clareon® IOLs are optically equivalent to AcrySof® IQ IOLs

Outstanding Spectacle Independence at All Distances[20^]

PANOPTIX®
is the only trifocal IOL with such robust spectacle independence data

13
studies

513
patients from 14 countries

Over 9 out of 10
patients achieved spectacle independence across all distances

^Based on AcrySof® IQ PanOptix® data Clareon® IOLs are optically equivalent to AcrySof® IQ IOLs

Advancements in the Clareon® Material and Design

Featuring an all-new material, design, and manufacturing process, Clareon® is Alcon's most advanced IOL.

- Maximal axial stability makes **for maximum refractive predictability**[5]
- Exceptional **rotational stability**[6,7]
- Designed to **reduce edge-associated glare** and **PCO**[8,21]
- Clareon® material provides exceptional clarity and is **glistening-free**[§,6,9-12]

[§]Defined as Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively

Long Lasting Glistening-free[§,11,12]

In long-term clinical studies, **Clareon® IOLs** were reported as glistening-free[§] over 3 and 9 years.[11-12]

No glistenings and surface light-scattering reported in a study by Oshika et al. from 1 to 9 years[11]

What are glistenings?



Photograph of patient implanted with **Clareon®** at 9 years[11]

[§]Defined as Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively

Significantly Less Glistenings than Other IOLs[22]

In an in vitro study, Clareon® IOLs demonstrated lower levels of glistenings compared with TECNIS* and Vivinex* IOLs‡,[22]

Glistening density *in vitro*†,[22]
(mean ± 95% CI, n=30 IOLs per group)



*Trademarks are the property of their respective owners.
‡Denotes statistical significance for comparison of slit lamp surface haze as determined by a one-way ANOVA (P<0.001) compared with Clareon®.
†Compared in vitro with TECNIS* OptiBlue* ZCB00V, TECNIS* ZCB00, Vivinex* XY-1, Eternity* Natural Uni W-60, and enVista* MX60.
(Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)

Alcon

Clareon® PanOptix® Toric
Trifocal IOL

Clareon® PanOptix® IOL: An Exceptional Visual Experience[2,3]

Full range of exceptional vision
with 20/20 vision at near, intermediate and far[3,23^]

Better contrast sensitivity°
vs AcrySof® IQ PanOptix®[15]

Less visual disturbances°
vs AcrySof® IQ PanOptix®[15]

Unsurpassed clarity & stability
with a glistening-free§ IOL material[5,12]

>3 Millions
PanOptix® IOLs have been **Implanted Globally[1]**

°Contrast sensitivity was significantly better in the Clareon PanOptix group at all degrees, including the area under the log contrast sensitivity function (p = 0.01); 6.3° = 0.019 vs 0.026; 4.0° = 0.02 vs 0.03; 2.5° = 0.026 vs 0.037; 1,6° = 0.045 vs 0.059; 1.0° 0.078 vs 0.105; 0.64° = 0.156 vs 0.201

§Defined as Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively

Alcon

Clareon® PanOptix®
Trifocal IOL &
Toric Trifocal IOL

Can I have your commitment to upgrade your patients to the Clareon® PanOptix® IOL?

Discover more on AlconExperienceAcademy.com

bit.ly/alcon-aea

Scan the QR-code to learn more about PanOptix® and Presbyopia Management

References

1. Alcon data on file, REF-24102, 2024
2. Clareon® PanOptix® Directions for Use
3. Modi et al. Visual and Patient-Reported Outcomes of a Diffractive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens. 2020 Sep 28;S0161-6420(20)30677-1
4. Lwowski C, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive EDOF and trifocal intraocular lenses. J Cataract Refract Surg 2021 Aug 18. doi: 10.1097/j.jcrs.0000000000000780
5. Lane et al. Evaluation of intraocular lens mechanical stability. J Cataract Refract Surg 2019 Apr;45(4):501-506
6. Alcon Data on File. [TDOC-0055470]
7. Clareon® Toric Directions for Use
8. Alcon Data on File. [TDOC-0053578]
9. Alcon Data on File. [TDOC-0057291]
10. Stanojcic N, O'Brart D, Hull C, et al. Visual and refractive outcomes and glistenings occurrence after implantation of 2 hydrophobic acrylic aspheric monofocal IOLs. J Cataract Refract Surg. 2020;46(7):986-994. doi:10.1097/j.jcrs.0000000000000201
11. Oshika T, Fujita Y, Inamura M, Miyata K. Mid-term and long-term clinical assessments of a new 1-piece hydrophobic acrylic IOL with hydroxyethyl methacrylate. J Cataract Refract Surg. 2020;46(5):682-687. doi:10.1097/j.jcrs.0000000000000142
12. Maxwell A, Suryakumar R. Long-term effectiveness and safety of a three-piece acrylic hydrophobic intraocular lens modified with hydroxyethyl-methacrylate: an open-label, 3-year follow-up study. Clin Ophthalmol. 2018;12:2031-2037. Published 2018 Oct 11. doi:10.2147/OPTH.S175060
13. The Galien Foundation Honors Excellence in Scientific Innovation at 2021 Prix Galien Awards Gala. Available at: https://www.prnewswire.com/news-releases/the-galien-foundation-honors-excellence-in-scientific-innovation- at-2021-prix-galien-awards-gala-301411801.html. Accessed December 19, 2023
14. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clin Ophthalmol. 2023;17:155-163.
15. Lee et al. Clinical outcomes of new multifocal intraocular lenses with hydroxyethyl methacrylate and comparative results of contrast sensitivity, objective scatter, and subjective photic phenomena. BMC Ophthalmology 2022; 22:379.

Please refer to relevant product direction for use and operator manual for complete list of indications, contraindications and warnings.

*Trademarks are the property of their respective owners

°Based on AcrySof® IQ PanOptix® data

References

16. Charness N, Dijkstra K, Jastrzembski T, et al. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society 52nd Annual Meeting, 2008. http://www.Academia.edu/477435/Monitor_Viewing_ Distance_for_Younger_and_Older_Workers. Accessed April 9, 2015.
17. Average of American OSHA, Canadian OSHA and American Optometric Assocation Recommendations for Computer Monitor Distances. www.aoa.org. (July, 2015).
18. Plagenhoef S, Evans FG, Abdelnour T. Anatomical data for analyzing human motion. Research Quarterly for Exercise and Sport. 1983;54,169-178.
19. What is the average male height? Average Height. http://www.averageheight.co/average-male-height. Accessed July 6, 2015
20. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmol Ther. 2023; Published online ahead of print. doi: 10.1007/s40123-023-00657-5.
21. Clareon® Monofocal Directions for Use
22. Werner L, Thatthamla I, Ong M, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL. J Cataract Refract Surg. 2019;45:1490-1497.
23. Alcon Data on File, 2021. AcrySof PanOptix Pooled Defocus Curve Memo.
24. Böhm, M et al. Defocus curve of four presbyopia correcting IOL designs. J Refract Surg 2019;45:1625
25. Alcon Data on File, 2017. [TDOC-0053487]
26. Miyata K, Honbo M, Matsunaga J, Minami K. Surface light scattering in intraocular lenses manufactured with the optimized production process: 12-month results. J Cataract Refract Surg. 2014;40(3):498–499.
27. Nishihara H, Yaguchi S, Onishi T, Chida M, Ayaki M. Surface scattering in implanted hydrophobic intraocular lenses. J Cataract Refract Surg. 2003; 29:1385–1388
28. Miyata K, Honbo M, Otani S, Nejima R, Minami K. Effect on visual acuity of increased surface light scattering in intraocular lenses. J Cataract Refract Surg. 2012;38:221–226.
29. Hayashi K, Hirata A, Yoshida M, Yoshimura K, Hayashi H. Long-term effect of surface light scattering and glistenings on intraocular lenses on visual function. Am J Ophthalmol 2012;154:240-251
30. Alcon Data on File, 2017. [TDOC-0053488]
31. Van der Mooren M, Franssen L, Piers P. Effects of glistenings in intraocular lenses. Biomedical Optics Express. 2013;4:1294-1304
32. Miyata A1, Uchida N, Nakajima K, Yaguchi S. Clinical and experimental observation of glistening in acrylic intraocular lenses. Jpn J Ophthalmol. 2001 Nov-Dec;45(6):564-9.

Please refer to relevant product direction for use and operator manual for complete list of indications, contraindications and warnings.

*Trademarks are the property of their respective owners

°Based on AcrySof® IQ PanOptix® data

What Defines a Pristine IOL?



SURFACE HAZE

SSNGs

GLISTENINGS

Surface haze can be seen immediately after implantation.[26]

Viewed through a slit lamp with off-axis illumination can appear as grainy matte texture, sandpaper or frosted glass appearance on the IOL surface.[26]

Surface Haze



Slit Lamp Image (25X) at 30° Illumination Angle Narrow Beam*[26]

*B&L enVista, MX60, 25.0 D.

Subsurface Nano-Glistenings (SSNGs) are observed after a year following implantation.[26-29]

Appear as a uniform milky surface scattering texture when viewed through a slit lamp with off-axis illumination.[26-29]

Scheimpflug Cross-Section Image at 45° angle*[30]

*Santen Eternity Natural Uni, W-60, 25.0D

SSNG



SURFACE HAZE | **SSNGs** | GLISTENINGS

Glistenings typically begin to appear over a 1-16 month period after implantation.[31,32]

Observed during slit lamp examinations as small reflections of light near the center region of the IOL bulk, they are cosmetic in nature and do not generally interfere with the patient's vision.[29,31]

Dark field Image showing glistenings in an IOL*[31]



*iSymm IOL, HOYA Surgical Optics, Inc.

Validated Patient Visual Quality

PanOptix® patient outcomes have been robustly tested with a questionnaire recognized by the FDA as validated for use with IOLs.[2,^]

Example of normal contrast sensitivity

Example of low contrast sensitivity

% of patients reported being bothered very much by

blurry vision

0%[2]

n=127 (blurry)

% of patients reported being bothered very much by

hazy vision

0%[2]

n=125 (hazy)

^Based on AcrySof® IQ PanOptix® data

Clareon® Continues Alcon's legacy of Minimal Axial Shift and Maximum Refractive Predictability[5]

- Unique design with STABLEFORCE Haptics to remain stable during compression[5]
- Clareon® and AcrySof® exhibit lower levels of axial displacement than other IOL platforms (ex: Vivinex, Tecnis, Envista)[5]



*Trademarks are the property of their respective owners.

Exceptional Rotational Stability[6,7]

95.3% of Clareon® PanOptix® Toric IOLs rotate

≤ 5°

between surgery and day 1 measures.[6]

Studies demonstrated an **absolute rotation of 1.8° at day 1 post-op and 2° at 6 months post-op** (n=124).[7]



Designed to Reduce Edge-Associated Glare and PCO[6,8]

Proprietary edge curvature minimizes glare



Precision edge design guards against PCO

- Featuring an advanced manufacturing process that creates a precision edge design[8]
- Designed to minimize edge-associated glare[8]
- Designed with a sharp posterior edge which has demonstrated low rates of PCO[8,21]

Lower levels of glistenings, surface haze and SSNGs[10-12,20]

Ultra-smooth optic delivers among the lowest levels of surface haze[22]

Delivers among the lowest levels of subsurface nano glistenings (SSNGs, in vitro)[22]



Clareon® is a glistening-free[§] IOL[10-12]

[§]Defined as Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively

Glistenings typically begin to appear over a 1-16 month period after implantation.[31,32]

Observed during slit lamp examinations as small reflections of light near the center region of the IOL bulk, they are cosmetic in nature and do not generally interfere with the patient's vision.[29,31]

Dark field Image showing glistenings in an IOL*[31]



*iSymm IOL, HOYA Surgical Optics, Inc.

Clareon®



Vivinex* XY-1



In an in vitro study, Clareon® IOLs demonstrated lower levels of glistenings compared with TECNIS* and Vivinex* IOLs‡,22

*Trademarks are the property of their respective owners.
‡Compared in vitro with TECNIS* OptiBlue* ZCB00V, TECNIS* ZCB00, Vivinex* XY-1, Eternity* Natural Uni W-60, and enVista* MX60.
(Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)

Clareon®



TECNIS* ZCB00



In an in vitro study, Clareon® IOLs demonstrated lower levels of glistenings compared with TECNIS* and Vivinex* IOLs‡,22

*Trademarks are the property of their respective owners.
‡Compared in vitro with TECNIS* OptiBlue* ZCB00V, TECNIS* ZCB00, Vivinex* XY-1, Eternity* Natural Uni W-60, and enVista* MX60.
(Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)

Clareon®



TECNIS* OptiBlue* ZCB00V



In an in vitro study, Clareon® IOLs demonstrated lower levels of glistenings compared with TECNIS* and Vivinex* IOLs‡,22

*Trademarks are the property of their respective owners.
‡Compared in vitro with TECNIS* OptiBlue* ZCB00V, TECNIS* ZCB00, Vivinex* XY-1, Eternity* Natural Uni W-60, and enVista* MX60.
(Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)